» Articles » PMID: 9862627

Immunizing Patients with Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or Gp100 Melanoma Antigens

Overview
Specialty Oncology
Date 1998 Dec 23
PMID 9862627
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the development of immunization strategies for patients with metastatic melanoma. With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations.

Methods: In phase I studies, 54 patients received escalating doses (between 10(7) and 10(11) plaque-forming units) of recombinant adenovirus encoding either MART-1 or gp100 melanoma antigen administered either alone or followed by the administration of interleukin 2 (IL-2). The immunologic impact of these immunizations on the development of cellular and antibody reactivity was assayed.

Results: Recombinant adenoviruses expressing MART-1 or gp100 were safely administered. One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. Other patients achieved objective responses, but they had received IL-2 along with an adenovirus, and their responses could be attributed to the cytokine. Immunologic assays showed no consistent immunization to the MART-1 or gp100 transgenes expressed by the recombinant adenoviruses. High levels of neutralizing antibody were found in the pretreatment sera of the patients.

Conclusions: High doses of recombinant adenoviruses could be safely administered to cancer patients. High levels of neutralizing antibody present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens.

Citing Articles

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.


The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.

Gray G, Chukwuma P, Eldaly B, Perera W, Brambley C, Rosales T Immunol Rev. 2025; 329(1):e13439.

PMID: 39804137 PMC: 11771984. DOI: 10.1111/imr.13439.


Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.

Al Hmada Y, Brodell R, Kharouf N, Flanagan T, Alamodi A, Hassan S Cancers (Basel). 2024; 16(2).

PMID: 38275910 PMC: 10814963. DOI: 10.3390/cancers16020470.


Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8 T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Zheng Y, Lu Z, Ding J, Jiang N, Wang J, Yang J Cancers (Basel). 2022; 14(18).

PMID: 36139670 PMC: 9497125. DOI: 10.3390/cancers14184512.


Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Ku M, Authie P, Bourgine M, Anna F, Noirat A, Moncoq F EMBO Mol Med. 2021; 13(12):e14459.

PMID: 34647691 PMC: 8646827. DOI: 10.15252/emmm.202114459.


References
1.
Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J . Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86(15):1159-66. DOI: 10.1093/jnci/86.15.1159. View

2.
Crystal R, McElvaney N, Rosenfeld M, Chu C, Mastrangeli A, Hay J . Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994; 8(1):42-51. DOI: 10.1038/ng0994-42. View

3.
Yang Y, Ertl H, Wilson J . MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1994; 1(5):433-42. DOI: 10.1016/1074-7613(94)90074-4. View

4.
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S . Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995; 154(8):3961-8. View

5.
Bronte V, Tsung K, Rao J, Chen P, Wang M, Rosenberg S . IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 1995; 154(10):5282-92. PMC: 2041892. View